INTRODUCTION
============

Worldwide, almost 600 000 new cases of head and neck cancer are reported each year.^[@r01]^ Alcohol drinking is an established risk factor for head and neck squamous cell carcinoma (HNSCC).^[@r02],[@r03]^ In general, ethanol is oxidized by alcohol dehydrogenase (ADH) enzymes to acetaldehyde, which is then further oxidized to acetate by aldehyde-dehydrogenase (ALDH) enzymes. This latter oxidation is largely dependent on the ALDH2 enzyme.^[@r04]^ The metabolism of ethanol leads to accumulation of acetaldehyde, which is toxic and established as a strong carcinogen, and differences in ethanol metabolism that result from polymorphisms in the genes that code for these enzyme affect cancer etiology among drinkers.^[@r05]^ The *ALDH2* Glu504Lys polymorphism (Single Nucleotide Polymorphism Database \[dbSNP\] ID, rs671), which has a catalytically inactive subunit, is known to interact with the association between alcohol drinking and HNSCC risk.^[@r06]--[@r13]^ Light drinkers with *ALDH2* Lys/Lys and Glu/Lys have 18 times and 5 times higher average peaks of acetaldehyde concentrations in blood, respectively, than moderate drinkers with *ALDH2* Glu/Glu.^[@r14]^ However, the prognostic value of alcohol drinking and *ALDH2* polymorphism on clinical outcome in patients with HNSCC remains unclear.^[@r15]--[@r21]^

Previously, we clarified the association between lifestyle factors and prognosis in HNSCC patients.^[@r22]^ Alcohol drinking is known to induce factors associated with cancer survival.^[@r23]--[@r25]^ This suggests that alcohol drinking might affect the survival of HNSCC patients and that *ALDH2* polymorphism might interact with this association.

Here, we conducted a retrospective cohort study to clarify the potential association of these factors among 267 patients treated for HNSCC at Aichi Cancer Center (ACC).

METHODS
=======

Patients
--------

We selected patients from the database of the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC), based at ACC in Nagoya, Japan. The HERPACC framework has been detailed elsewhere.^[@r26],[@r27]^

Briefly, 23 408 HERPACC-enrolled, first-visit outpatients treated between January 2001 and November 2005 at ACC were asked to provide blood samples and information on lifestyle factors. Among those who participated, 22 727 patients (97.1%) completed a self-administered questionnaire including lifestyle factors, which was checked by a trained interviewer, and approximately 60% provided blood samples. The HERPACC study was approved by the Institutional Ethics Review Board of ACC, and all participants provided written informed consent.

HERPACC-enrolled patients diagnosed as having primary head and neck cancer who met the following criteria were included: (a) no prior history of cancer; (b) no malignant neoplasms of the salivary glands, nasopharynx, nasal, or paranasal sinuses (these cancers were excluded, as they have a distinct etiology); (c) histological diagnosis of squamous cell carcinoma; (d) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2^[@r28]^; and (e) availability of information about drinking status and *ALDH2* genotype. Ultimately, 267 patients were eligible for this study.

Treatment and follow-up
-----------------------

We considered surgery and chemoradiotherapy (CRT) or radiotherapy (RT) with or without induction chemotherapy (ICT) as treatment modalities for HNSCC. Attending surgeons determined treatment of each individual patient based on clinical disease stage, primary tumor site, and PS. Patients were followed up with a history and physical examination, complete blood cell count, and imaging examination every 3 to 6 months for 5 years after their treatment. We confirmed vital and disease status by checking medical records at the date of last follow-up visit. Vital status in patients lost to follow-up was confirmed by a census registration conducted annually.

Genotyping of *ALDH2*
---------------------

We extracted DNA from the buffy coat fraction with a DNA Blood mini kit (Qiagen, Tokyo, Japan) or BioRobot EZ1 and EZ1 DNA Blood 350 mL Kit (Qiagen). We genotyped *ALDH2* Glu504Lys polymorphism (rs671) by the TaqMan method (Applied Biosystems, Foster City, CA, USA). The quality control of genotyping was assessed statistically by using the Hardy-Weinberg test and by retyping of a random sampling of 5% of subjects.

Assessment of drinking and smoking status
-----------------------------------------

Details of the assessment of drinking and smoking status have been described elsewhere.^[@r22]^ Our questionnaire consisted of items related to smoking and drinking habits in the period preceding the development of the present symptoms or reason for visit to ACC.

Levels of alcohol consumption were divided into four groups: non-, light, moderate, and heavy drinkers. Moderate drinkers were defined as individuals who consumed alcoholic beverages in a daily amount of ≥46 g ethanol (equivalent to two Japanese drinks) but \<69 g ethanol for ≥5 days per week. Heavy drinkers were defined as individuals who consumed alcohol beverages in a daily amount of ≥69 g ethanol for ≥5 days per week. Light drinkers were defined as individuals who consumed alcoholic beverages in a daily amount of \<46 g ethanol for \<5 days per week. The remaining patients were categorized as non- or light drinkers using data from the HERPACC study for head and neck cancers.^[@r29]^

Cumulative exposure to cigarette smoking was quantified as pack-years of smoking (PY), the product of the number of packs consumed per day and number of years of cigarette smoking. We divided patients into four groups based upon PY: non-, light (PY \< 20), moderate (PY 20--39), and heavy smokers (PY ≥ 40).

Statistical methods
-------------------

The primary endpoint of this study was disease-free survival (DFS), which was defined as the number of days from the beginning of treatment to the date of relapse. The associations between drinking status (0: non, 1: light, 2: moderate, and 3: heavy), *ALDH2* genotypes (0: Glu/Lys, 1: Glu/Glu, and 2: Lys/Lys), and DFS were evaluated by the Kaplan-Meier product-limit method and uni- and multivariate Cox proportional hazards models. Confounders considered in the multivariate analyses were age (continuous), sex (male or female), ECOG PS (0--2), smoking status (non- vs light vs moderate vs heavy), Union for International Cancer Control (UICC) stage (1--4), and treatment method (surgery or CRT/RT).

In addition, the interaction between drinking status and *ALDH2* genotype was examined by adding an interaction term between the two items in multivariate models. Distribution of patient characteristics was assessed by the χ^2^ test or Fisher's exact test, as appropriate. All statistical analyses were performed using the software STATA ver. 10 (Stata Corp, College Station, TX, USA). All tests were two-sided, and *P*-values of \<0.05 were considered statistically significant.

RESULTS
=======

Patient characteristics and survival
------------------------------------

Table [1](#tbl01){ref-type="table"} summarizes subject characteristics in the study. Median age was 61 (range, 21--78) years, and median follow-up time was 5.0 years (range, 0.7 months--9.1 years). Drinking was more prevalent among males than females. Similarly, drinking was more prevalent among smokers, but less prevalent among oral cavity cancer patients than patients without oral cavity cancer. Five-year DFS among all patients was 55.5% (95% confidence interval \[CI\], 49.1--61.4%).

###### Characteristics of head and neck squamous cell carcinoma patients according to drinking status and *ALDH2* genotype

  Characteristics             Drinking status   *P*-value     *ALDH2* genotype (rs671)   *P*-value                                                         
  --------------------------- ----------------- ------------- -------------------------- ------------- --------- ------------- ------------- ------------- -------
  Median age (range)          61 (23--78)       60 (21--77)   61 (42--77)                61 (32--78)             61 (21--78)   61 (30--78)   56 (25--71)    
  Sex                                                                                                                                                       
   Male                       32 (49)           90 (87)       43 (93)                    51 (98)       \<0.001   82 (74)       122 (86)      12 (86)       0.048
   Female                     33 (51)           14 (13)       3 (7)                      1 (2)         29 (26)   20 (14)       2 (14)                      
  ECOG PS                                                                                                                                                   
   0                          29 (45)           55 (53)       26 (57)                    27 (52)       0.491     59 (53)       71 (50)       7 (50)        0.922
   1                          33 (51)           43 (41)       19 (41)                    25 (48)       48 (43)   65 (46)       7 (50)                      
   2                          3 (4)             6 (6)         1 (2)                      0 (0)         4 (4)     6 (4)         0 (0)                       
  UICC stage                                                                                                                                                
   I                          12 (19)           21 (20)       6 (13)                     8 (15)        0.172     19 (17)       23 (16)       5 (36)        0.502
   II                         22 (33)           21 (20)       6 (13)                     12 (23)       26 (23)   31 (22)       4 (29)                      
   III                        12 (19)           18 (17)       10 (22)                    6 (12)        21 (19)   23 (16)       2 (14)                      
   IV                         19 (29)           44 (43)       24 (52)                    26 (50)       45 (41)   65 (46)       3 (21)                      
  Primary tumor site                                                                                                                                        
   Oral cavity                34 (52)           56 (54)       19 (41)                    16 (31)       \<0.001   61 (55)       58 (41)       6 (42)        0.003
   Oropharynx                 11 (17)           16 (15)       4 (9)                      16 (31)       20 (18)   23 (16)       4 (29)                      
   Hypopharynx                3 (5)             15 (15)       11 (24)                    15 (29)       8 (7)     36 (25)       0 (0)                       
   Larynx                     17 (26)           17 (16)       12 (26)                    5 (9)         22 (20)   25 (18)       4 (29)                      
  Treatment method                                                                                                                                          
   Surgery                    22 (34)           39 (37)       19 (41)                    15 (29)       0.585     44 (40)       47 (33)       4 (29)        0.477
   CRT or RT                  43 (66)           65 (63)       27 (59)                    37 (71)       67 (60)   95 (67)       10 (71)                     
  Smoking status                                                                                                                                            
   Non                        30 (46)           20 (19)       3 (6)                      2 (4)         \<0.001   28 (25)       22 (16)       5 (36)        0.217
   Light (PY \< 20)           7 (11)            21 (20)       9 (20)                     4 (8)         19 (17)   20 (14)       2 (14)                      
   Moderate (20 ≤ PY \< 40)   11 (17)           25 (24)       11 (24)                    19 (36)       24 (22)   40 (28)       2 (14)                      
   Heavy (40 ≤ PY)            14 (21)           38 (37)       22 (48)                    27 (52)       39 (35)   58 (41)       4 (29)                      
   Unknown                    3 (5)             0 (0)         1 (2)                      0 (0)         1 (1)     2 (1)         1 (7)                       

ECOG, Eastern Cooperative Oncology Group; UICC, Union for International Cancer Control; PS, performance status; CRT, chemoradiotherapy; RT, radiotherapy; PY, pack-years of smoking; ALDH2; aldehyde dehydrogenase 2.

Drinking status was classified as follows: non, light (\<46 g ethanol or \<5 days/week), moderate (46--68 g ethanol for ≥5 days/week), and heavy (≥69 g ethanol for ≥5 days/week).

Impact of drinking status and *ALDH2* genotype on DFS
-----------------------------------------------------

Figure [1](#fig01){ref-type="fig"} shows the Kaplan-Meier survival curves for drinking status. Drinking status was associated with DFS in HNSCC patients with marginal statistical significance (5-year DFS: 67.9% \[95% CI, 53.8--78.4%\] for non-drinkers, 57.6% \[95% CI, 47.4--66.6%\] for light drinkers, 46.1% \[95% CI, 30.8--60.1%\] for moderate drinkers, and 43.5% \[95% CI, 29.3--56.9%\] for heavy drinkers; *P* = 0.088).

![Kaplan Meier survival curves for drinking status in patients with head and neck squamous cell carcinoma. Five-year disease-free survival was 67.9% (95% confidence interval \[CI\], 53.8--78.4%) for non-drinkers, 57.6% (95% CI, 47.4--66.6%) for light drinkers, 46.1% (95% CI, 30.8--60.1%) for moderate drinkers, and 43.5% (95% CI, 29.3--56.9%) for heavy drinkers (logrank test, *P* = 0.088).](je-26-292-g001){#fig01}

Figure [2](#fig02){ref-type="fig"} shows the Kaplan-Meier survival curves for *ALDH2* genotype. *ALDH2* genotype was not significantly associated with DFS in HNSCC patients (5-year DFS: 85.7% \[95% CI, 53.9--96.2%\] for Lys/Lys, 56.2% \[95% CI, 47.4--64.1%\] for Glu/Lys, and 50.5% \[95% CI, 40.3--59.7%\] for Glu/Glu; *P* = 0.154).

![Kaplan Meier survival curves for aldehyde dehydrogenase 2 (*ALDH2*) genotype in patients with head and neck squamous cell carcinoma. Five-year disease-free survival was 85.7% (95% confidence interval \[CI\], 53.9--96.2%) for *ALDH2* Lys/Lys patients, 56.2% (95% CI, 47.4--64.1%) for *ALDH2* Glu/Lys patients, and 50.5% (95% CI, 40.3--59.7%) for *ALDH2* Glu/Glu patients (logrank test, *P* = 0.154).](je-26-292-g002){#fig02}

Table [2](#tbl02){ref-type="table"} shows the results of uni- and multivariate analysis for DFS. In univariate analysis, drinking status showed a significant trend in decreasing DFS (*P*~trend~ = 0.013). However, neither drinking status nor *ALDH2* genotype showed a significant association with DFS in multivariate analysis.

###### Impact of drinking status and *ALDH2* genotype on disease-free survival in patients with head and neck squamous cell carcinoma

  Variable                   *n*   *n* (relapse)   Univariate analysis   Multivariate analysis                               
  -------------------------- ----- --------------- --------------------- ----------------------- ------- ------ ------------ -------
  Drinking status                                                                                                            
   Non                       65    16              1.00                  reference               ---     1.00   reference    ---
   Light                     104   31              1.38                  0.83--2.29              0.210   1.09   0.58--2.08   0.785
   Moderate                  46    20              1.80                  1.02--3.18              0.042   1.32   0.64--2.71   0.453
   Heavy                     52    16              1.90                  1.09--3.31              0.023   1.22   0.58--2.57   0.607
   *P*~trend~                                                                                    0.013                       0.503
                                                                                                                             
  *ALDH2* genotype (rs671)                                                                                                   
   Glu/Glu                   111   39              1.00                  reference               ---     1.00   reference    ---
   Glu/Lys                   142   41              0.98                  0.68--1.40              0.914   0.76   0.51--1.13   0.178
   Lys/Lys                   14    3               0.34                  0.11--1.08              0.067   0.51   0.14--1.84   0.303
   *P*~trend~                                                                                    0.212                       0.123

ALDH2, aldehyde dehydrogenase 2; CI, confidence interval; HR, hazard ratio.

Drinking status was classified as follows: non, light (\<46 g ethanol or \<5 days/week), moderate (46--68 g ethanol for ≥5 days/week), and heavy (≥69 g ethanol for ≥5 days/week).

Adjusted for age, sex, performance status, clinical disease stage, primary tumor site, smoking, and definitive treatment.

Interaction between drinking status and *ALDH2* genotype on DFS
---------------------------------------------------------------

Kaplan-Meier survival curves of DFS for drinking status according to *ALDH2* genotype are shown in Figure [3](#fig03){ref-type="fig"}. Drinking status was significantly associated with DFS in *ALDH2* Glu/Glu patients (59.4% \[95% CI, 30.9--79.4%\] for non-drinkers, 60.6% \[95% CI, 44.8--73.2%\] for light drinkers, 44.6% \[95% CI, 23.5--63.8%\] for moderate drinkers, and 21.1% \[95% CI, 5.8--42.7%\] for heavy drinkers; *P* = 0.023).

![Kaplan Meier survival curves of disease-free survival for drinking status according to aldehyde dehydrogenase 2 (*ALDH2*) Glu/Glu genotype. Five-year disease-free survival among ALDH2 Glu/Lys patients was 63.6% (95% confidence interval \[CI\], 43.4--78.2%) for non-drinkers, 55.1% (95% CI, 40.8--67.3%) for light drinkers, 47.1% (95% CI, 25.2--66.3%) for moderate drinkers, and 56.8% (95% CI, 37.3--72.3%) for heavy drinkers (logrank test, *P* = 0.764). Respective rates among ALDH2 Glu/Glu patients were 59.4% (95% CI, 30.9--79.4%), 60.6% (95% CI, 44.8--73.2%), 44.6% (95% CI, 23.5--63.8%), and 21.1% (95% CI, 5.8--42.7%) (logrank test, *P* = 0.023).](je-26-292-g003){#fig03}

In multivariate analysis, drinkers with *ALDH2* Glu/Glu showed a significant trend toward decreased DFS (*P*~trend~ = 0.029; Table [3](#tbl03){ref-type="table"}). In contrast, among patients with *ALDH2* Glu/Lys, drinking status showed no significant association with DFS. In addition, we observed suggestive heterogeneity between drinking status and *ALDH2* genotype on DFS (*P* for heterogeneity = 0.100).

###### Impact of drinking status according to *ALDH2* genotype on disease-free survival in patients with head and neck squamous cell carcinoma

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *ALDH2* genotype\   Drinking status   *P* for\                                                                                                                                                                 
  (rs671)                               heterogeneity                                                                                                                                                            
  ------------------- ----------------- --------------- ------ ------------ ------- ---- ---- ------ ------------- ------- ---- ---- ------ ------------ ------- ----- ----- ------ ------------ ------- ------- -------
  Glu/Glu             20                5               1.13   0.42--3.01   0.814   48   13   1.05   0.48--2.31    0.895   22   11   1.77   0.73--4.29   0.204   21    10    2.34   0.93--5.86   0.070   0.029   0.138

  Glu/Lys             33                9               1.00   reference    ---     54   17   1.27   0.57--2.86    0.557   24   9    1.18   0.47--2.96   0.718   31    6     0.86   0.35--2.14   0.748   0.164   

  Lys/Lys             12                2               0.49   0.10--2.27   0.359   2    1    2.00   0.22--18.04   0.535   0    0    ---    0            0       ---   ---                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALDH2, aldehyde dehydrogenase 2; HR, hazard ratio; CI, confidence interval.

Drinking status was classified as follows: non, light (\<46 g ethanol or \<5 days/week), moderate (46--68 g ethanol for ≥5 days/week), and heavy (≥69 g ethanol for ≥5 days/week).

Adjusted for age, sex, performance status, clinical disease stage, primary tumor site, smoking, and definitive treatment.

DISCUSSION
==========

In this study, we demonstrated that high pre-treatment alcohol consumption worsens DFS in HNSCC patients. This effect was evident only among the *ALDH2* Glu/Glu patients, suggesting that it might differ by *ALDH2* genotype. To our knowledge, this is the first report to evaluate the impact of alcohol drinking combined with *ALDH2* genotype on clinical outcome in HNSCC patients.

Although the mechanism behind this association between drinking status and survival of HNSCC patients remains unclear, several explanations appear plausible based on existing evidence. First, alcohol drinking may induce activation of NF-κB, a transcription factor that has been linked with the transformation of cells and survival of cancer stem cells.^[@r30]^ Additionally, NF-κB regulates the expression of genes associated with the apoptosis, proliferation, invasion, angiogenesis, and metastasis of cancer. Second, alcohol consumption may induce TP53 mutation, which is associated with HNSCC survival.^[@r23],[@r31]^ Third, alcohol drinking may modify the DNA methylation profile in HNSCC cells. DNA methylation modifications may affect the prognosis of HNSCC.^[@r32]^ Fourth, alcohol drinking damages normal mucosa in the head and neck region. Long-term continuation of this mucosal damage, called "field cancerization", may be associated with a predisposition to relapse or development of a second primary tumor (SPT).^[@r25]^ However, the incidence of SPT was not associated with drinking status in this study (data not shown).

In addition, our findings suggest that the association between alcohol drinking and prognosis of HNSCC may differ by *ALDH2* genotype. Although this mechanism is also unclear, we speculate that this association might be affected by alcohol dependence.^[@r33]^ Individuals who are heterozygous or homozygous for the Lys allele of *ALDH2* Glu504Lys polymorphism (rs671) have greatly reduced ability to metabolize acetaldehyde, which greatly decreases their risk for alcohol dependence.^[@r34]^ After definitive treatment, *ALDH2* Glu/Glu patients might maintain higher levels of alcohol consumption than *ALDH2* Glu/Lys patients. However, this point should be assessed in other studies evaluating post-treatment or under-treatment drinking behavior according to *ALDH2* genotype.

Our study has several methodological strengths. First, because clinicians involved in the care of study patients were not aware of the exposure status examined in this study, information bias was less likely to have been introduced. Second, because the analyses were adjusted for established prognostic factors, including clinical disease stage and PS, the observed associations were theoretically independent. However, the exclusion of residual confounding by unevaluated factors, such as human papilloma virus (HPV) infection, cannot be completely ruled out.

Several methodological limitations also warrant mention. First, our information on drinking habits reflected pre-treatment drinking status only, and we were therefore unable to evaluate the impact of changes in drinking behavior during the study. Second, the prognostic value of drinking-related comorbidities, including coronary artery disease, cerebral infarction, peripheral vascular disease, and chronic liver disease, might bias this study. If death induced from these comorbidities were not uncommon in the heavy drinkers, our study would have overestimated the prognostic value of heavy drinking in HNSCC patients. Actually, while the ratio of patients who died from HNSCC alone was 58.8%, information on the cause of death was unavailable for 29.5%. Third, although we tried to minimize the effect of bias by considering potential confounders in multivariate analysis, the impact of residual confounding, including that due to HPV infection, cannot be fully excluded. Finally, the moderate sample size may have limited the ability of the study to detect differences between the groups.

We concluded that high pre-treatment alcohol drinking worsened DFS in patients with HNSCC. This effect might be clearer among patients with *ALDH2* Glu/Glu. Our results suggest a possible gene-environmental interaction in the clinical outcome of HNSCC patients. Replication in a larger study is warranted.
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